Pivotal clinical studies confirmed both the promising pre-clinical data and the prognostic relevance of both total and M2 TAM, in which CD68/CD163 double-positive M2 TAM were associated with an increased micro-vessel density and reduced survival, independently of the tumor stage [104,105,106,107,108]. This evidence concerns the gene CD68 and neoplasm.